Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.

You are viewing the site in preview mode

Skip to main content

Table 1 Summary of patient demographics (n = 192)

From: Evidence of SARS-CoV-2 convergent evolution in immunosuppressed patients treated with antiviral therapies

 

N or Range

% or Median

Gender

 Male

102

53%

 Female

90

47%

Age range (Median)

 Male

28–108

68

 Female

28–95

67

Vaccination

 Vaccinated (≥ 1 dose)

190

99%

 Unvaccinated or Unknown

2

1%

Immune status

 Immunosuppresseda

75

39%

 Not Immunosuppressed

117

61%

COVID-related hospitalization

 Hospitalized

122

64%

 Not hospitalized

70

36%

Diabetes mellitus

 Yes

105

55%

 No

87

45%

  1. aImmunosuppression due to active treatment for solid tumor and hematologic malignancies, recipients of solid organ transplant, patients with autoimmune diseases, or HIV infection as included in Supplemental Dataset 1
Back to article page

Virology Journal

ISSN: 1743-422X